Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
Takeaways: Health Canada has authorized PrUpgolyv (golimumab injection), giving Canada its first Simponi biosimilar and further extending JAMP Pharma’s BioJAMP immunolo...
Takeaways: Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...
Takeaways: Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among ...
Takeaways: AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...
Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
Takeaways: Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...
